These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 11502791)

  • 1. Epitope mapping of tsh receptor-blocking antibodies in Graves' disease that appear during pregnancy.
    Kung AW; Lau KS; Kohn LD
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3647-53. PubMed ID: 11502791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epitopes for thyroid-stimulating antibodies in Graves' sera: a possible link of heterogeneity to differences in response to antithyroid drug treatment.
    Kim WB; Cho BY; Park HY; Lee HK; Kohn LD; Tahara K; Koh CS
    J Clin Endocrinol Metab; 1996 May; 81(5):1758-67. PubMed ID: 8626830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A change from stimulatory to blocking antibody activity in Graves' disease during pregnancy.
    Kung AW; Jones BM
    J Clin Endocrinol Metab; 1998 Feb; 83(2):514-8. PubMed ID: 9467567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epitopes for thyroid stimulating and blocking autoantibodies on the extracellular domain of the human thyrotropin receptor.
    Tahara K; Ishikawa N; Yamamoto K; Hirai A; Ito K; Tamura Y; Yoshida S; Saito Y; Kohn LD
    Thyroid; 1997 Dec; 7(6):867-77. PubMed ID: 9459630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epitope heterogeneity of thyrotropin receptor-blocking antibodies in Graves' patients as detected with wild-type versus chimeric thyrotropin receptors.
    Grasso YZ; Kim MR; Faiman C; Kohn LD; Tahara K; Gupta MK
    Thyroid; 1999 Jun; 9(6):531-7. PubMed ID: 10411114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in epitopes for thyroid-stimulating antibodies in Graves' disease sera during treatment of hyperthyroidism: therapeutic implications.
    Kim WB; Chung HK; Lee HK; Kohn LD; Tahara K; Cho BY
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1953-9. PubMed ID: 9177413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two Graves' disease patients who spontaneously developed hypothyroidism after antithyroid drug treatment: characteristics of epitopes for thyrotropin receptor antibodies.
    Chung HK; Kim WB; Park DJ; Kohn LD; Tahara K; Cho BY
    Thyroid; 1999 Apr; 9(4):393-9. PubMed ID: 10319947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of separate determinants on the thyrotropin receptor reactive with Graves' thyroid-stimulating antibodies and with thyroid-stimulating blocking antibodies in idiopathic myxedema: these determinants have no homologous sequence on gonadotropin receptors.
    Kosugi S; Ban T; Akamizu T; Kohn LD
    Mol Endocrinol; 1992 Feb; 6(2):168-80. PubMed ID: 1349156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graves' immunoglobulins activate phospholipase A2 by recognizing specific epitopes on thyrotropin receptor.
    Di Cerbo A; Di Paola R; Menzaghi C; De Filippis V; Tahara K; Corda D; Kohn LD
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3283-92. PubMed ID: 10487700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prevalence and clinical significance of blocking thyrotropin receptor antibodies in untreated hyperthyroid Graves' disease.
    Kim WB; Chung HK; Park YJ; Park DJ; Tahara K; Kohn LD; Cho BY
    Thyroid; 2000 Jul; 10(7):579-86. PubMed ID: 10958310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The extracellular domain of the TSH receptor has an immunogenic epitope reactive with Graves' IgG but unrelated to receptor function as well as determinants having different roles for high affinity TSH binding and the activity of thyroid-stimulating autoantibodies.
    Kosugi S; Akamizu T; Takai O; Prabhakar BS; Kohn LD
    Thyroid; 1991; 1(4):321-30. PubMed ID: 1726785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No increase of blocking type anti-thyrotropin receptor antibodies during pregnancy in patients with Graves' disease.
    Amino N; Izumi Y; Hidaka Y; Takeoka K; Nakata Y; Tatsumi KI; Nagata A; Takano T
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5871-4. PubMed ID: 14671183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid function parameters and TSH-receptor antibodies in healthy subjects and Graves' disease patients: a sequential study before, during and after pregnancy.
    González-Jiménez A; Fernández-Soto ML; Escobar-Jiménez F; Glinoer D; Navarrete L
    Thyroidology; 1993 Apr; 5(1):13-20. PubMed ID: 7508738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of thyroid-stimulating antibody with Graves' thyroid-stimulating hormone-binding antibody.
    Ochi Y; Kajita Y; Hamazu M; Nagata A
    Horm Res; 2003; 59(5):222-8. PubMed ID: 12714785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
    J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of classification of Graves' disease according to the characteristics of TSH receptor antibodies.
    Kim WB; Chung HK; Park YJ; Park DJ; Lee HK; Cho BY
    Korean J Intern Med; 2001 Sep; 16(3):187-200. PubMed ID: 11769578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitope heterogeneity of thyroid-stimulating antibodies predicts long-term outcome in Graves' patients treated with antithyroid drugs.
    Kim TY; Park YJ; Park DJ; Chung HK; Kim WB; Kohn LD; Cho BY
    J Clin Endocrinol Metab; 2003 Jan; 88(1):117-24. PubMed ID: 12519839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.